TY - JOUR T1 - Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis JF - Journal of Clinical Pathology JO - J Clin Pathol SP - 709 LP - 714 DO - 10.1136/jcp.2006.039917 VL - 60 IS - 6 AU - Paulette Mhawech-Fauceglia AU - Rhakee Saxena AU - Shaozeng Zhang AU - Luigi Terracciano AU - Guido Sauter AU - Arundhuti Chadhuri AU - Francois R Herrmann AU - Remedios Penetrante Y1 - 2007/06/01 UR - http://jcp.bmj.com/content/60/6/709.abstract N2 - Background: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin’s lymphoma (B-NHL), Hodgkin’s lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored. Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections. Results: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder. Conclusion: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas. ER -